251 results on '"Ghesquieres, H."'
Search Results
2. CO7.4 - Evolution de la qualité de vie des patients atteints d'un lymphome diffus à grandes cellules B après la première ligne de traitement et participant à la cohorte prospective REALYSA
3. Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma
4. Sarcoïdose et lymphome : étude multicentrique, à propos de 46 cas
5. Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective ‘proof of concept’ phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)
6. Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers
7. LISOCABTAGENE MARALEUCEL (LISO‐CEL) VERSUS STANDARD OF CARE (SOC) AS SECOND‐LINE THERAPY IN LARGE B‐CELL LYMPHOMA (TRANSFORM STUDY): SUBGROUP ANALYSES BY PRIOR THERAPY RESPONSE
8. COMBINING CD19‐4‐1BBL (RO7227166) WITH GLOFITAMAB IS SAFE AND SHOWS EARLY EFFICACY IN PATIENTS SUFFERING FROM RELAPSED OR REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA
9. TRANSCEND FL: PHASE 2 STUDY RESULTS OF LISOCABTAGENE MARALEUCEL (LISO‐CEL) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)
10. VERY LONG‐TERM FOLLOW‐UP OF RITUXIMAB MAINTENANCE IN YOUNG PATIENTS WITH MANTLE CELL LYMPHOMA INCLUDED IN THE LYMA TRIAL, A LYSA STUDY.
11. Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA group
12. Correction to: Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma
13. Tandem haematopoietic stem cell transplantation versus single cell transplant and BV maintenance in relapsed/refractory Hodgkin lymphoma: A matched cohort analysis from the LYSA
14. Mortalité et causes associées dans le syndrome d’activation histiolymphocytaire : une analyse de causes multiples de décès
15. Tandem versus single haematopoietic stem cell transplant and BV maintenance in relapsed/refractory Hodgkin lymphoma: A matched cohort analysis from the LYSA.
16. P611: NEXT-CLL: A NEW NGS-BASED METHOD FOR RAPID ASSESSMENT OF IGHV MUTATIONAL STATUS IN CHRONIC LYMPHOID LEUKEMIA
17. P1186: A LARGE FRENCH REAL WORLD MULTICENTRIC PROSPECTIVE COHORT OF PATIENTS WITH LYMPHOMA (REALYSA STUDY): DESCRIPTION OF THE DIFFUSE LARGE B CELL LYMPHOMA PATIENTS IN REAL WORLD IN FRANCE
18. HEV infection in stem cell transplant recipients-retrospective study of EBMT Infectious Diseases Working Party
19. Adrenal lymphoma: presentation, management and prognosis
20. A randomised phase II study of the efficacy, safety and cost-effectiveness of pegfilgrastim and filgrastim after autologous stem cell transplant for lymphoma and myeloma (PALM study)
21. Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d’Etude des Lymphomes de l’Adulte (GELA)
22. P14.54 Primary central nervous system lymphoma of the spinal cord: a LOC network cohort study
23. Sarcoidosis and lymphoma: a comparative study
24. First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)—a systematic review and individual patient data meta-analysis
25. A risk model for severe anemia to select cancer patients for primary prophylaxis with epoetin α: a prospective randomized controlled trial of the ELYPSE study group
26. BRENTUXIMAB VEDOTIN AS CONSOLIDATION TREATMENT IN PATIENTS WITH STAGE I/II CLASSICAL HODGKIN'S LYMPHOMA AND A POSITIVE FDG‐PET AFTER 2 CYCLES OF ABVD: A LYSA PHASE 2 STUDY
27. OUTCOMES IN LATER‐LINES OF THERAPY FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: RESULTS FROM THE INTERNATIONAL SCHOLAR‐5 STUDY
28. AMAHRELIS : ADCETRIS MAINTENANCE AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN HODGKIN LYMPHOMA : A REAL LIFE STUDY FROM SFGMTC AND LYSA GROUPS
29. EARLY POSITRON EMISSION TOMOGRAPHY RESPONSE‐ADAPTED TREATMENT IN LOCALIZED DIFFUSE LARGE B‐CELL LYMPHOMA (AAIPI=0) : RESULTS OF THE PHASE 3 LYSA LNH 09‐1B TRIAL
30. Relapsed / Refractory International Prognostic Index (R/R-IPI): An international prognostic calculator for relapsed/refractory diffuse large B-cell lymphoma
31. Lipid trait variants and the risk of non-hodgkin lymphoma subtypes: a mendelian randomization study
32. Commercialanti-CD19 CART cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center
33. Lipid trait variants and the risk of non-hodgkin lymphoma subtypes: a mendelian randomization study
34. Genetically Determined Height and Risk of Non-hodgkin Lymphoma
35. Preparation of a booklet on intensive chemotherapy with stem cell autograft and two questionnaires assessing the quality of the information given, in an attempt to improve patient care: N1288
36. Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma
37. Severe interstitial pneumonitis following rituximab and bleomycin-containing combination chemotherapy
38. Genetic overlap between autoimmune diseases and non-Hodgkin lymphoma subtypes
39. Evaluation of core needle biopsy as a substitute to open biopsy in the diagnosis of soft-tissue masses
40. Reply to the letter to the editor ‘Maintenance lenalidomide in primary CNS lymphoma’ by Rubenstein et al.
41. POOLED RESULTS OF THREE ANNUAL COHORTS FROM AN OBSERVATIONAL PROSPECTIVE STUDY DESCRIBING BRENTUXIMAB VEDOTIN USE IN ROUTINE PRACTICE IN FRANCE FOR HODGKIN LYMPHOMA: INTERIM ANALYSIS
42. COMPARISON OF CLINICAL SCORING SYSTEMS IN AGGRESSIVE B-CELL LYMPHOMAS (BCL): AN INDIVIDUAL PATIENT-LEVEL ANALYSIS ACROSS INTERNATIONAL TRIAL
43. A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma
44. A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma
45. Corrigendum to ‘Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers’: [Annals of Oncology Volume 29, Issue 3, March 2018, Pages 715-723]
46. Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials
47. Comparison of overall survival of lisocabtagene maraleucel (liso‐cel) versus standard of care (SOC) adjusting for crossover in second‐line (2L) R/R large B‐cell lymphoma.
48. Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma
49. First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)—a systematic review and individual patient data meta-analysis
50. MANAGEMENT PATTERNS AND OUTCOME OF PATIENTS WITH PRIMARY CNS LYMPHOMA (PCNSL) IN FRANCE DURING 2011-2016. A LOC NETWORK STUDY
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.